Mirum Pharmaceuticals has completed its acquisition of privately held Bluejay Therapeutics, adding the investigational monoclonal antibody brelovitug to its pipeline. The asset, currently in the AZURE Phase 3 program for chronic hepatitis delta virus (HDV), carries Breakthrough Therapy and PRIME designations, with topline data expected in late 2026.

Why brelovitug could become a cornerstone of Mirum’s expanded liver disease portfolio

With this acquisition, Mirum Pharmaceuticals is not just adding an investigational therapy—it is expanding the scope of its ambition in rare hepatology. Brelovitug is a pan-genotypic, fully human IgG1 monoclonal antibody designed to neutralize HDV and HBV virions by targeting HBsAg, a shared surface antigen. In doing so, it addresses one of the most lethal viral coinfections in hepatology. Chronic hepatitis delta virus is widely regarded as the most severe form of viral hepatitis, with no approved therapies in the United States and Europe, and a prognosis that sees over half of diagnosed patients progressing to liver failure or death within a decade.

Mirum’s portfolio already covers genetically driven cholestatic liver diseases with LIVMARLI, CHOLBAM, and CTEXLI. But with brelovitug, it now moves into virally driven hepatology for the first time. This is a major axis shift in the company’s positioning—from a focus on pediatric and metabolic hepatology to potentially addressing viral hepatology in a broader adult population. Industry observers note that this could allow Mirum to compete in a wider arena while retaining its rare disease identity.

Importantly, brelovitug is being advanced under both U.S. FDA Breakthrough Therapy and EMA PRIME designations. These regulatory signals are often viewed as indicators of expedited development potential, although they do not guarantee approval. What they do enable, however, is a faster and more interactive development pathway—critical for a company that now has multiple late-stage assets potentially heading toward overlapping launch timelines between 2026 and 2028.

How AZURE Phase 3 differs from past HDV development efforts and what still needs to be proven

The AZURE program builds directly on brelovitug’s strong showing in Phase 2, where the candidate achieved complete HDV RNA suppression alongside ALT normalization in many patients. Yet the Phase 3 bar remains high. The AZURE program is built on open-label designs targeting virologic and biochemical co-endpoints, rather than surrogate markers alone. While this design could accelerate time to data, it may introduce complexity when interpreting response durability and clinical outcomes.

What makes this noteworthy is that brelovitug is mechanistically distinct from bulevirtide, the first conditional HDV approval in the EU. Bulevirtide is a viral entry inhibitor targeting NTCP, while brelovitug neutralizes circulating virions and subviral particles. This difference matters clinically, as the therapeutic goal in HDV is not just to block reinfection but to reduce viral load to undetectable levels—potentially enabling functional cure strategies.

Clinicians tracking the space believe brelovitug’s greatest advantage could lie in its pan-genotypic activity and strong safety profile. Injection site reactions were the most common adverse event in Phase 2, which may make it preferable to drugs with hepatic or renal toxicity concerns. However, pivotal data will need to confirm these signals at scale. Biotech investors are also watching whether the primary endpoint design in AZURE will be accepted by regulators as sufficiently robust for BLA filing.

What the deal structure reveals about Mirum’s capital planning and appetite for pipeline expansion

This acquisition was not opportunistic—it was pre-funded. Mirum secured $268.5 million in private placement financings concurrent with the closing, ensuring immediate capital for brelovitug’s development and potential commercialization. The company structured the deal with a mix of cash, stock, and performance-based milestones, signaling long-term integration rather than a bolt-on asset flip.

This deal architecture aligns with Mirum’s pattern of disciplined capital deployment across its pipeline. Notably, the company chose to internalize both brelovitug and the Bluejay team, rather than just license the asset. This suggests a broader intent: to create a fully integrated rare liver disease platform company, with viral and genetic pathologies under one roof.

At the same time, Mirum indicated it is still evaluating Bluejay’s other investigational programs. That leaves open the possibility of future divestments or partnerships, particularly if those assets fall outside Mirum’s core liver disease focus. Industry observers will be watching closely whether Mirum pursues pipeline breadth or stays focused on execution.

Why HDV represents a commercially risky but potentially transformative opportunity

Despite the severity of HDV, the addressable market is relatively small. Prevalence estimates suggest roughly 230,000 patients across the U.S. and Europe. However, there is substantial geographic variability, with higher incidence in certain immigrant and underserved populations. This poses a classic rare disease challenge: how to build commercial infrastructure for a dispersed, underdiagnosed, and under-referred patient base.

This is not uncharted territory for Mirum. The company’s launch of LIVMARLI in Alagille syndrome and PFIC required similar navigation of small, high-need patient groups. However, HDV patients may not reside within pediatric hepatology centers of excellence but instead within infectious disease and general hepatology clinics—posing a new market access challenge.

Reimbursement dynamics are also a concern. While brelovitug’s clinical profile may warrant premium pricing, payers are likely to demand clear outcomes-based evidence, particularly for a first-in-class asset. Pricing strategies may also be complicated by potential future competitors in HDV, including follow-on antivirals and therapeutic vaccines currently in early-stage development.

Strategic signal: A transition from pediatric genetic hepatology to pan-hepatic rare disease

The acquisition of Bluejay Therapeutics marks a strategic pivot for Mirum from exclusively pediatric, genetically rooted liver diseases to a broader, pan-hepatology ambition. This has implications not only for future licensing and R&D but also for how the company is perceived by investors, regulators, and clinicians.

By anchoring this pivot to a well-validated Phase 3 program with regulatory fast-track designations, Mirum is signaling that it intends to lead—not follow—in rare liver disease innovation. Yet that leadership will now depend on flawless execution of the AZURE trial, successful post-acquisition integration, and the ability to scale commercial infrastructure beyond current pediatric channels.

In short, Mirum is now operating at a new level of risk and reward. If brelovitug delivers, it could solidify the company’s status as a cross-indication hepatology innovator. If it falters, the capital investment and integration effort could constrain Mirum’s ability to advance its remaining pipeline assets.

  AZURE trial, Bluejay Therapeutics, brelovitug, HDV, hepatitis delta virus, Mirum Pharmaceuticals, monoclonal antibodies, Phase 3 trials, rare liver disease